EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY 4.0

Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer

Eric Van Cutsem iD, Rona Yaeger iD, Jean-Pierre Delord, Josep Tabernero iD, Lillian L Siu iD, Michel Ducreux, Salvatore Siena, Elena Elez iD, Stefan Kasper, Thomas Zander, Neeltje Steeghs, Danielle Murphy und 2 weitere

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad210 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2023. Verfasst von Eric Van Cutsem und 13 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Oncology, University Hospitals Gasthuisberg, Leuven and KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Array Biopharma in collaboration with Novartis, National Institutes of Health Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Activating RAS gene mutations occur in approximately 55% of patients with metastatic colorectal cancer (mCRC) and are associated with poorer clinical outcomes due to epidermal growth factor receptor (EGFR) blockade resistance. Combined EGFR and mitogen-activated protein kinase (MEK) inhibition may extend response to EGFR inhibition and overcome acquired resistance. This phase Ib/II dose escalation trial evaluated the safety and activity of dual inhibition with binimetinib (MEK1/2 inhibitor) and panitumumab (EGFR inhibitor [EGFRi]) in patients with RAS mutant or BRAF wild type (WT)/RAS WT mCRC.

Methods

Phase Ib dose escalation started with binimetinib 45 mg twice daily plus panitumumab 6 mg/kg administered every 2 weeks. In the phase II study, patients with measurable mCRC were enrolled into 4 groups based on previous anti-EGFR monoclonal antibody therapy and RAS mutational status.

Results

No patients in the phase Ib portion (n = 10) had a response; 70% of patients had stable disease. In the phase II portion (n = 43), overall response rate (ORR, confirmed) was 2.3% with one partial response in the RAS WT group, DCR was 30.2%, and median progression-free survival was 1.8 months (95%CI, 1.6-3.3). All patients experienced ≥1 adverse event, with the most common being diarrhea (71.7%), vomiting (52.8%), nausea (50.9%), fatigue (49.1%), dermatitis acneiform (43.4%), and rash (41.5%). Most patients required treatment interruption or dose reduction due to difficulties tolerating treatment.

Conclusions

The combination of binimetinib and panitumumab had substantial toxicity and limited clinical activity for patients with mutant or WT RAS mCRC, independent of EGFRi treatment history (Trial registration: NCT01927341).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsColonic NeoplasmsRectal NeoplasmsHumansPanitumumabBenzimidazolesErbB ReceptorsAntineoplastic Combined Chemotherapy ProtocolsProto-Oncogene Proteins p21(ras)

Stichwörter der Autor:innen

RAS mutationRAS wild typebinimetinibcolorectal cancerpanitumumab

Substanzen

PanitumumabbinimetinibBenzimidazolesErbB ReceptorsProto-Oncogene Proteins p21(ras)

Autor:innen und Institutionen

  • Digestive Oncology, University Hospitals Gasthuisberg, Leuven and KU Leuven, Leuven, Belgium.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Medical Oncology Department, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.
  • Medical Oncology Department, Vall d'Hebron Campus Hospital and Institute of Oncology (VHIO), IOB-Quiron, UVic-UICC, Barcelona, Spain.
  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Department of Medical Oncology, Gustave Roussy, Cancer Campus, Université Paris-Saclay, Villejuif, France.

ORCID-Profile: Eric Van Cutsem, Rona Yaeger, Josep Tabernero, Lillian L Siu, Elena Elez

Förderung

  • NCI NIH HHS
  • Array Biopharma in collaboration with Novartis
  • National Institutes of Health Cancer Center

Zitieren

APA

Van Cutsem, E., Yaeger, R., Delord, J. P., Tabernero, J., Siu, L. L., Ducreux, M., Siena, S., Elez, E., Kasper, S., Zander, T., Steeghs, N., Murphy, D., Edwards, M., & Wainberg, Z. A. (2023). Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyad210

Vancouver

Van Cutsem E, Yaeger R, Delord JP, Tabernero J, Siu LL, Ducreux M, et al. Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer. The Oncologist. 2023. doi:10.1093/oncolo/oyad210

BibTeX
@article{VanCutsem2023,
  author = {Van Cutsem, Eric and Yaeger, Rona and Delord, Jean-Pierre and Tabernero, Josep and Siu, Lillian L and Ducreux, Michel and Siena, Salvatore and Elez, Elena and Kasper, Stefan and Zander, Thomas and Steeghs, Neeltje and Murphy, Danielle and Edwards, Michelle and Wainberg, Zev A},
  title = {Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad210}
}
Kostenlos starten →